Practical Concerns about the Metrics and Methods of Financial Outcome Measurement in Antimicrobial Stewardship Programs: A Narrative Review

Fazlollah Keshavarzi, PharmD, MPharm
Department of Clinical Pharmacy, School of Pharmaceutical Sciences, UCSI University, Kuala Lumpur, Malaysia

Correspondence:
Fazlollah Keshavarzi, PharmD, MPharm; School of Pharmaceutical Sciences, UCSI University, Taman Connaught, Cheras, P.O. Box: 56000, Kuala Lumpur, Malaysia
Tel: +60 174724527
Email: fazlollahk@yahoo.com
Received: 01 August 2021
Revised: 23 August 2021
Accepted: 28 September 2021

Abstract
Emerging pathogens in the meantime of paucity of new antibiotics discovery, put antimicrobial stewardship in the center of attention, to preserve the existing antimicrobial effect. Implementation of antimicrobial stewardship programs, however, needs approval from healthcare system managers. The approval process can be enhanced, when the beneficial effects of stewardship programs are supported by both clinical and financial evidence. Focusing on the financial outcome evaluation, the practitioners who run the stewardship programs, may choose certain methods and metrics, depending on the clinical setting scale and type, available human resources, and budget. The wise selection of the methods and metrics warrants a comprehensive insight of the existing methods and metrics, deployed by typically published works that set good examples to follow. This review is an attempt to provide such an insight along with typical relevant examples for each metric and method.

Keywords
● Anti-bacterial agents
● Cost-benefit analysis
● Health care economics and organizations
● Antimicrobial stewardship

Introduction
The financial analysis of an antimicrobial stewardship program (ASP) is a great concern of healthcare managers, policymakers, and governments. Clinicians may be more interested in the clinical outcomes and reduced microbial resistance in implemented ASPs, but the implementation, or even the initiation of the program would be dependent on the anticipated positive financial benefit in many occasions. Using financial metrics to assess the ASPs is still challenging, due to the involvement of interwoven clinical objectives. Moreover, the positive financial impact of ASP may appear initially, but plateau after two to three years. Therefore, keeping the administration interested in running ASP would not be easy.

Referring to the existing literature, an increasing number of published ASP projects with financial objectives can be retrieved. The researchers and practitioners often focus on certain metrics and methods, rather than a comprehensive and integrated analytical approach, due to the practical limitations in their clinical settings. Selecting the metrics and methods for forthcoming ASP
projects requires a compact guide that brings all important metrics and methods together to enhance and improve both implementation and analysis of outcomes from the financial point of view. This is an attempt to provide a collection of all important metrics and methods of financial analysis of ASPs, using typical recent publications that represent a wide variety of the objectives, metrics, and methods. The researchers who plan for running ASP, will find this review a useful practical guide for selecting the most suitable endpoints and methods in their projects.

Previously, Naylor and colleagues tried to find out whether ASPs are cost-effective. They used the following keywords in PubMed to look up the relevant resources: ((cost-effectiveness) OR (cost-benefit) OR (cost-utility) OR (cost effectiveness) OR (cost benefit) OR (cost utility) OR (cost saving)) AND (( antimicrobial stewardship) OR (antibiotic stewardship)). We used the same search strategy for exploring the conducted research and publications in ASP with financial objectives from 2000 to 2021, to reveal the deployed methods and metrics of ASP implementation. The Scopus database was also searched, using similar keywords. The retrieved number of results from PubMed and Scopus was 613 and 2979, respectively. After screening the titles and abstracts and omitting the duplications, the most relevant publications were selected for this review (table 1).

In the first section of this review, the authors will provide an insight into the common financial metrics of ASP. The next section will discuss the methods by which the stated metrics can be measured.

**Metrics**

**Cost**

Cost is the most common interested financial metric in ASP studies. Besides, the clinical endpoints, reducing healthcare costs is a major objective of ASPs, without which it is hard to convince healthcare managers to adopt ASP. However, the evaluation and analysis of the impact of ASP on cost is not a straightforward matter.

The simplest approach is probably the comparison of antimicrobial cost before and after the implementation of ASP. Xiao and colleagues reported the impact of a nationwide national formulary restriction in China on the procurement and frequency of use of antibiotics during the 2010 to 2016 period. The proportion of antibiotic to all drugs procurement dropped from 22% to 13% during this period, where the microbial resistance shows the desired profile.

On a smaller scale, Sick and others conducted a retrospective cohort study that investigated the impact of an ASP in a pediatric hospital in a six-year period. The intervention was a restriction policy on 33 antibiotics. The cost-saving was calculated using the below equation.

\[
\text{Cost Savings} = \left( \frac{\text{cost if } 100\% \text{ approval}}{\text{actual charge}} \right) - \frac{\text{restricted dose} \times \text{average charge per restricted dose}}{\text{average approval rate}} - \frac{\text{restricted doses} \times \text{average charge per restricted doses}}{\text{actual approval rate}}
\]

Cost, however, is not limited to the direct cost of procurement of antimicrobials. A comprehensive cost analysis of ASP should include a variety of fixed, variable, potential, operational, and societal costs.

Fixed costs may vary with time, rather than the quantity of output, such as rental and staff salaries. On the other hand, variable cost alteration is a function of the level of output, such as food, service fees, and supplies. Some of the authors have considered the fixed cost a synonym of indirect cost, where variable cost can be substituted with direct or marginal cost. Examples of direct cost in the context of antimicrobial resistance in hospital settings, as outlined by Howard and colleagues, are general hospital costs per day/per bed (either by specialty or by department/ward), cost of patient isolation (supplies, housekeeping, waste disposal, increased portable testing services, and increased staffing), antimicrobial acquisition costs, antimicrobial administration costs, nursing staff time for specialized nurses, the occurrence of other infections and complications, the occurrence of other procedures, laboratory costs for screening procedures, physician staff time, infection control staff, lab testing for diagnosis.

Actual versus potential cost is also discussed by some researchers. Antimicrobial cost analysis, sometimes is about prospective cost evaluation, and the estimated inflation rate may be considered, where actual inflation rate might differ from anticipated ones, or a low-price generic product might be purchased, a drug shortage might be encountered, etc.

Implementation (operational) cost refers mainly to the staff wage and fringe benefits, allocated computers and software, pertinent maintenance costs, training sessions, and circulars/educational materials. It is probably the most important parameter from the viewpoint of managers, when they want to decide about running the program. According to a systematic review, the type of intervention was primarily therapy evaluation and providing review and feedback in most of the reported ASPs (63%), followed by altered therapy guidelines (16%)
Table 1: Selected antimicrobial stewardship publications with financial objectives.

| Author/Year | Metrics                                                                 | Method                                                                 |
|-------------|--------------------------------------------------------------------------|------------------------------------------------------------------------|
| Pakyz 2009  | Carbapenems use as days of therapy per 1,000 patient days, incidence rate, and proportion of carbapenem-resistant P. aeruginosa isolates | General linear mixed models, a survey to assess antibacterial restriction and antibiogram construction, antibiograms to assess resistance, carbapenems use as days of therapy per 1000 patient days (DOT/1000 PD) |
| Lima 2011   | Pre/post cumulative susceptibility test, DDD/1000 patient days            | Retrospective, pre- and post-restriction analysis                       |
| Ahmad 2014  | Appropriateness of group two carbapenem therapy                           | Retrospective analysis of all carbapenem use                           |
| Yoon 2014   | Susceptibility of Acinetobacter baumannii to Group two carbapenems        | Before-and-after study following implementation of a program of carbapenem-use stewardship |
| Viale 2015  | 30-month incidence rates of carbapenem-resistant Enterobacteriaceae (CRE)-positive rectal cultures and bloodstream infections (BSIs) | Quasi-experimental study, Poisson regression                           |
| Serrano 2015| Carbapenems cost and DDD/100 OBD                                       | Prospective, descriptive before-after analysis                          |
| Tagashira Y 2016 | Monthly carbapenem use as days of therapy (DOT) per 1,000 patient days, hospital mortality rates, and average hospitalization duration | Before-after, prospective interventional, once-weekly post-prescription prospective audit |
| Delgado 2015 | Monthly ertapenem use in DOT/1000 adjusted patient days (APD), the rates of carbapenem nonsusceptible P.aeruginosa, Escherichia coli and Klebsiella pneumoniae | Retrospective pre-post implementation                                       |
| Seah 2017  | Intervention acceptance and outcomes, including carbapenem utilization (DDD), length of stay, hospitalization charges, 30-day readmission, and mortality rates | Retrospective analysis of the outcome of the review-and-feedback approach based on IDSA recommendations |
| Hwang 2018  | DOT/1000 patient-days, trends of antimicrobial resistance, in-hospital mortality rate per 1000 patient-days | Interrupted time series analysis                                       |
| Zhang 2019  | Evaluating the rationality of carbapenem use                              | A point-score system Retrospective                                      |
| Johnk 2019  | Change in carbapenem DOT across 23 hospitals after a stewardship intervention and determine changes in morbidity, mortality, and resistance rates. | Retrospective, multicenter, sequential period analysis                  |
| Ruttimann 2004 | Comparative DDD of the restricted antibiotics, before and after the implementation of the stewardship program, mortality and rehospitalization rate, length of stay, relapse during hospitalization | Quasi-experimental, before-after study                                   |
| Sick 2013   | Cost analysis and cost-saving after the restrictions on 33 antibiotics    | Longitudinal, retrospective cohort                                      |
| Ansari 2003 | Antibiotics use before and after the implementation of an ‘Alert Antibiotics’ intervention | Drug use and cost analysis by interrupted time series with segmented regression analysis |
| Gums 1999   | The median length of stay after the intervention, time-specific mortality risk, median patient charges for radiology, laboratory, pharmacy, and room, and median hospital costs | Prospective, randomized controlled study                                |
| Scheetz 2009 | Cost per QALY                                                             | Probability-based cost-effectiveness using QALY                        |
| Hamblin 2012 | Mean LOS, mean annual wage for pharmacists at general medical and surgical hospitals subtracted from the total cost savings | Retrospective cost-saving analysis after PharmD intervention           |
| Lin 2013    | Costs, consumption (DDD/1,000 patient-days), the percentage of antimicrobial agents in total drug costs | Retrospective cost-saving after educational intervention               |
| Garcia-Rodriguez 2019 | Cost of treatment, inpatient days, and hospital readmission, antibiotic consumption as defined daily doses (DDD) per 100 occupied bed days | Pre- and post-intervention descriptive analysis                        |
| Delory 2013 | Carbapenems consumption (DDD/1000 patient-days), the median length of stay, and mortality rate | Before-after, vancomycin-controlled interrupted time-series            |
| Mouwen 2020 | Duration of IV therapy, length of hospitalization                        | Historically controlled prospective intervention, educating physicians, handing out pocket-sized cards, and providing switch advice in the electronic patient record |
| Niwa 2012   | Antimicrobial use density, treatment duration, duration of hospital stay, the occurrence of antimicrobial-resistant bacteria, and medical expenses | Prospective, guideline-based, pre-post intervention prescription analysis |
and antibiotic restriction/preauthorization (12%). It is expected that variation in the cost of implementation depends on the type and scope of the intervention. However, according to a recently published systematic review, the association between the type of ASP implementation and implementation cost is not strong. In most of the ASPs, the implementation cost is negligible, as the intervention is limited to post-prescribing review and feedback, and existing full-time practitioners handle the process, with no additional cost. However, there are reports of ASP operational costs, as big as 243%, which is attributed to the intervention strategy, i.e., the strategies such as altered therapy guidelines

| Author/Year   | Metrics                                                                 | Method                                                                 |
|---------------|-------------------------------------------------------------------------|------------------------------------------------------------------------|
| Chandrasekhar 2019 | Parenteral antimicrobial administration, cost of antibiotic therapy, DDD/100 Bed days | Cost minimization analysis of IV to oral conversions, post-intervention audit |
| Dik 2015 | Implementation costs, cost-saving, investment return | Cost-minimization analysis through comparing audited patients with a historic cohort with the same diagnosis-related groups |
| Slayton 2015 | Antimicrobial Use and Resistance (AUR), Clostridium difficile infection (CDI) control | Markov model with a five-year time horizon, Cost-benefit analysis, sensitivity analyses for intervention effectiveness and cost |
| Bhavnani 2008 | Cost as three strata: drug acquisition costs, the first stratum plus preparation, dispensing, administration costs, and the cost of treatment of antibiotic-related adverse events and clinical failures, and the previous two strata plus LOS per diem costs. | Cost-effectiveness analysis |
| Collins 2019 | Procalcitonin (PCT)-guided antibiotic use in ICU for sepsis | Cost-minimization and cost-utility analyses, single-center, retrospective cross-sectional |
| McKinnell 2018 | Drug cost, total treatment cost | Decision-analytic model for cost-effective drug utilization |
| Okumura 2016 | (I) Hospital length of stay/patient-day, (II) cost of defined daily doses (DDD)/patient, (III) resources to provide microbiological and imaging diagnosis of infections, and (IV) human resources workload per day. | Cost-effectiveness using Markov model followed by deterministic one-way sensitivity analysis |
| Ruiz-Ramos 2017 | Consumption of antimicrobials, as well as the incidence of Clostridium difficile infections (CDI) | Cost-effectiveness analysis followed by sensitivity analysis |
| Voermans 2019 | Length of hospital stay | Cost-effectiveness analysis, decision algorithm |
| So 2018 | Antimicrobial utilization per month, in defined daily dose (DDD), normalized to 100 patient-days | Retrospective observational time-series study |
| Gutierrez 2019 | Comparative antimicrobial consumption, number of defined daily doses per 100 occupied bed days (DDD/100 OBD) | Consensus by a panel of experts on infectious diseases, microbiology and antimicrobial therapy, through a modified Delphi method |
| Thabit 2021 | DOT/1000 PD, specific antibiotic use (narrow-spectrum β-lactams, non-carbapenem antipseudomonal β-lactams, carbapenem, anti-MRSA agents | Linear regression (β coefficient) |
| Xiao 2020 | Antibiotic procurement and consumption data and antibiotic resistance surveillance data | Descriptive and frequency analysis |
| Jover-Saenz 2020 | Consumption of antimicrobials expressed in DDD per 100 OBDS | Prospective intervention study with historic cohort (before and after) |
| Mewes 2019 | Costs and effects of Procalcitonin-guided care on LOS, costs per patient (treatment costs and productivity losses), costs per antibiotic day avoided | Application of a health economic decision model to compare the costs and effects |
| Stocker 2020 | Absolute antibiotic consumption, DDD/100 OBs, cost saving | Retrospective, pre-/post-observational comparison |
| Onorato 2020 | Antibiotic consumption, the mean length of stay and the antibiotic expense | Prospective, interventional, interrupted time series analysis |
| Penalva 2020 | Quarterly antibiotic use (prescription and collection by the patient), DDD per 1000 inhabitants per day | Quasi-experimental intervention, interrupted time series analysis |
| Scott 2019 | Treatment costs, intervention costs, the value of statistical life, which was used to estimate the economic value of morbidity and mortality risk reductions | Net present value model to assess social costs and benefits |
| Vazin 2018 | Cost-saving, all-cause in-hospital mortality, the median length of hospital stay | Interventional, prospective study |

DOT: Days of therapy; PD: Patient day; QALY: Quality-adjusted life year; LOS: Length of hospital stay; DDD: Defined daily dose; OB: Occupied bed days; IDSA: Infectious diseases society of America; MRSA: Methicillin-resistant *Staphylococcus aureus*
and antibiotic restriction lists of pre-authorized agents do not impose a significant cost, whereas therapy evaluation, review, and/or feedback may increase the operational cost.54

A comprehensive cost evaluation of ASP may not ignore the societal costs, which include costs to the insurance company, costs to the patient, and indirect costs due to the loss of productivity.55 To consider the societal costs, Roberts and colleagues focused primarily on the excess mortality costs due to antimicrobial-resistant infections (ARI). They multiplied the number of deaths attributable to ARI by the lost productivity cost (in 2000 US dollars) for each age group.

For survivors of the ARIs, they considered the attributable length of stay multiplied by the daily cost for lost productivity in the year 2000.56 Although this work covers one of the main elements of societal costs, some other important elements, such as insurance costs and indirect patient costs were neglected.

Michaelidis and others suggested four methods to estimate the components of the incremental societal cost of antibiotic resistance associated with hospitalization, second-line inpatient antibiotic use, second-line outpatient antibiotic use, and finally antibiotic stewardship.57 The authors aimed to investigate and estimate poorly understood and hidden downstream societal costs of antibiotic resistance, attributable to ambulatory antibiotic prescribing. In terms of antibiotic stewardship, for instance, their focus is on the physician and pharmacist salary and educational costs. The article provides clues about how to estimate each of those cost components. Meanwhile, depending on the purpose of the study, this article is a good example of how different the components of societal costs can be. For example, when the objective of a study shifts from the cost evaluation of a specific condition to cost-saving derived from a specific intervention, the components of cost analysis may vary remarkably. Hamblin and colleagues addressed 26 elements of cost-saving to analyze the impact of PharmD intervention in the prevention of adverse drug reactions,23 from prevented adverse drug events and antibiotic consultation to the length of stay.

**Surrogate Metrics of Cost**

Antibiotics procurement may not provide the most accurate and reliable indicator of the financial impact of ASP, as it is not inclusive enough and can be confounded by many other parameters, such as hospital occupancy rate, price variation over time, or brand. Defined Daily Dose (DDD), length of hospital stay (LOS), or days of therapy (DOT) are some indicators of cost variation in general, and antibiotics use, specifically.

Shifting from general procurement (and expenditure, as an alternative) to Defined Daily Dose (DDD) (usually with 100 or 1000 occupied bed days as the denominator) helps to standardize antibiotic use and subsequently provides a metric for comparing the financial outcome of ASP before and after implementation or from center to center.57

DDD is adopted by WHO and defined as the average adult dose recommended for the main indication, as reflected by the Anatomical Therapeutic Chemical (ATC) classification.58 DDDs per 1000 population per day is interpreted, as the proportion of the population that receives the interested medicine on any given day. DDDs per 100 bed-days (adjusted for occupancy rate) is used more frequently in hospital settings, which provides a measure of inpatients that receive a DDD.59 For antibiotics that are typically being used in a short period, DDDs per inhabitant per year are preferred. This provides an estimate of the number of days, for which each person is treated with the antibiotic in a year.60 Patient-day or bed-day is often the denominator for DDD calculations in hospitals. The discharge day would not be counted to avoid the inflation of the denominator by partial days.59

Ruttimann’s study, for instance, is a quasi-experimental, before-afterstudy that analyzed the financial impact of an antimicrobial stewardship program for a period of four years.18 The implemented program was mandatory approval for restricted antibiotics (such as ceftriaxone, ceftazidime, piperacillin-tazobactam, imipenem-cilastatin, and vancomycin) as well as a comprehensive educational program. The primary endpoint of this study was a comparative defined daily dose (DDD) of the restricted antibiotics, before and after the implementation of the stewardship program. At the same time, some clinical endpoints of drug therapy, such as mortality and rehospitalization rate, length of stay, relapse during hospitalization, and so on were investigated to ensure the cost-saving may not aggravate the clinical outcomes. Where the focus of the ASP is limited to a particular class of antibiotics, any cost analysis of such an ASP must consider the potential for the clinicians to switch from the given antibiotics to an alternative antibiotic, to bypass the audit or prescription limitations. Therefore, the potential alternative antibiotics should be identified and brought into analysis to ensure that the overall antibiotic consumption has been evaluated properly.25

Some researchers suggested a potential
change in the consumption of the third-generation cephalosporins, piperacillin-tazobactam, and quinolones, when ASP targeted carbapenems.26

More recently, a selected committee of Spanish Societies of Hospital Pharmacy and Infectious Diseases and Clinical Microbiology published the consensus on hospitals' antibiotic use indicators.39 It is an advisable list of particular antibiotic classes as priority-based target antibiotics in ASPs.

Length of hospital stay (LOS) is one of the major endpoints of all ASPs. This is because LOS is on one hand a clinical indicator of ASP success, and on the other hand an important parameter, through which the cost-saving can be evaluated. The financial aspect of LOS is tightly related to the evaluation of the cost of the hospital per day. An example of a hospital cost analysis is the analysis of University of Malaya Medical Centre (UMMC) services, published in 2012. It reported the average length of stay (ALOS) for the medical and surgical wards as 6.7 days (SD 8.886) and 5.6 days (SD 9.005), respectively. According to this report, the cost per diem for medical and surgical wards was 641.15 Malaysian Ringgits (~USD 153), and 1,085.48 Malaysian Ringgits (~USD 260), respectively.61 These rates can be considered as the basis of cost calculations at any time, where the medical services inflation rates are considered.

A comprehensive example of inpatient cost evaluation is the TrendWatch Chartbook 2016,62 that provides detailed components of inpatient cost evaluation. A 2019-adjusted average inpatient hospital expense per day is also accessible online.61 Nevertheless, referring to LOS as an indicator of cost analysis faces complexities, as some authors have pointed out. Firstly, the cost of a single additional day of hospital stay is much different from critical care to non-critical care inpatients. Secondly, the cost of an additional day of hospital stay reduces by time, i.e., the cost of the 20th day of hospital stay can be as low as 20% of the second day of admission.63 Some researchers argued that providing a cost analysis based on the observed difference in LOS may not be feasible due to the inevitable differences among the antibiotics consumers who participate in different studies, as well as the difference between the severity of the infections among the treatment and control groups in the implemented ASP.64 However, the Kaplan-Meier plot in a Japanese ASP report confirms a drop in LOS after the implementation of ASP on parenteral antibiotics.28 This statistically significant one-day reduction in LOS was reported to cause US$1.95 million, and US$3.92 million to be saved in the two periods of ASP. The authors calculated the hospital charges with the inclusion of 40% diagnosis–procedure combination (DPC) of the mean unit charge for the hospital stay and the number of patients receiving antibiotic injections. LOS, as a metric of ASP, has been used in multiple studies with various methodologies.32, 35, 37, 43, 45

Days of therapy (DOT) have been used by some researchers as a metric of ASP. Monthly carbapenems use as DOT per 1000 patient days is reported with a significant reduction of carbapenems use by half.12 The segmented regression analysis of an interrupted time series confirmed the finding. Some other typical ASP studies with DOT as one of the study metrics have been published in recent years.13, 15, 64 Voermans and others is a comprehensive ASP cost-effective analysis that integrated LOS for both ICU and general wards, and DOT to come up with a procalcitonin-guided decision algorithm.37

It is important to identify the trends and turning points of variation in cost or other metrics, when an ASP is being analyzed over time. Interrupted time series analysis and longitudinal regression are ideal statistical approaches to address this matter.45, 46 The variables that potentially confound the analysis should be addressed. First, the severity of the disease should be adjusted to ensure that the compared patient groups (before/after ASP implementation or ASP interference adherent/nonadherent cases) are reasonably analogous. For this purpose, a generic instrument of illness severity assessment can be deployed for all included patients.65 The second potential confounder is the patients’ ages that warrant the variable adjustment.

In general, LOS remains a superior metric of clinical and cost-saving analysis of ASP, compared to the days of therapy (DOT) or DDD, which are disease-specific.66

Methods of ASP Financial Evaluation

The financial methods of ASP evaluation are the same as the general healthcare economics evaluation methods. Many of these methods can technically be categorized under the cost-effectiveness umbrella. However, the specific characteristics of the interested end-points in cost-benefit, cost-minimization, or cost-utility analyses suggest that the discussion is focused on each technique.

Cost-Effectiveness
Despite all available pieces of evidence
of beneficial outcomes of ASP and technical improvements, the thorough assessment of cost remains a complicated and unsolved problem.67

A multicentered randomized trial that evaluated the cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia, categorized the cost as three strata. The first stratum was drug acquisition costs, the second stratum included the first stratum plus preparation, dispensing, administration costs, and the cost of treatment of antibiotic-related adverse events and clinical failures. The third stratum was the previous two strata plus LOS per diem costs. The effectiveness was evaluated based on the clinical success, failure, or intermediate response of the patients.32

Collins and colleagues reported the cost-effectiveness of procalcitonin (PCT)-guided antibiotic use, where the effectiveness is stated in terms of quality-adjusted life years (QALYs).33 The researchers classified the cost variables as antibiotic therapy, PCT assay, and attributable costs (septicemia, nephrotoxicity, Clostridium difficile infection). LOS was classified under ‘duration variables’ along with other parameters.

Designing a decision tree, usually the Markov model, is very common in cost-effectiveness studies. The key question is sometimes a comparison of two specific drugs34 and sometimes two antimicrobial programs.35 The decision tree enhances revealing the outcomes variety, as well as potential confounders. However, the important concern that remains in cost-effectiveness analyses of ASPs is the complexity of anticipation of saved cost due to the prevention of future infections.68

Cost-Benefit

Slayton and colleagues attempted to provide a cost-benefit analysis of multifaceted infection control and antimicrobial stewardship program from the federal payer perspective.31 This study focused on the epidemiologic and economic value of the implementation of a multifaceted Clostridium difficile infection (CDI) control program at US acute care hospitals, using TreeAge Pro Suite software to construct a Markov model. The basis of calculation of effectiveness was a United Kingdom report of a 59% reduction in the number of CDI cases after the implementation of multifaceted infection control and antimicrobial stewardship program. They used the Bureau of Labour Statistics to take the wage of personnel into account. Other cost elements, such as laboratory supplies and contracts, extramural funding, and development and support of NHSN modules were adopted from CDC annual program budgets from the Office of Chief Financial Officer. Based on the model, the cost-beneficial analysis showed that $2.5 billion (95% credible interval: $1.2 billion to $4.0 billion) could be saved over a five-year horizon.

Cost-Minimization

The objectives of cost-minimization analysis are very close to cost-saving analyses. The cost-minimization analysis of the outcome of an ASP can be a suitable approach for investigating the short-term impact of ASP. The drawback of the cost-minimization ASP analysis is stated to not address the long-term impacts of ASP, especially the impact of the ASP on the emergence of microbial resistance.68

The analysis of the financial impact of conversion of parenteral to oral antibiotic therapy is a suitable area for application of the cost-minimization approach in ASP due to the involvement of a limited number of variables, as well as the short duration to observe and evaluate the outcomes. Controlled interventional studies are of course the best type of designs for such an analysis.29

A framework of the cost-minimization model to measure the direct costs and benefits of ASP is suggested.30 This model is based on a day two case-audit by a multi-disciplinary ASP team. The one-year financial impact of the post-audit intervention in 114 cases was compared with that of a 30-month control cohort. The subgroup analysis based on the Diagnosis Related Group (DRG) codes was performed by the researchers to address modifying disease-related factors. A pre-existing estimated cost of €716 per patient per day was deployed in this study. The overhead costs (including building costs, maintenance, equipment, personnel costs for daily care) were included in these estimations, whereas procedures were excluded, since a reduction in LOS did not influence the number of procedures substantially.

Conclusion

The objectives of antimicrobial stewardship programs are generally classified as either clinical or financial objectives. Although the financial objectives are not the primary objectives of the ASPs from the viewpoint of clinicians, in the absence of a positive perspective of financial output, it would be difficult to acquire the approval of the managers for conducting ASPs. A profound understanding of relevant
methods and metrics, in accordance with the particular healthcare center, allows the clinicians to develop the ASP protocol wisely with an augmented likelihood of positive financial output and subsequently, stepping forward for a wider scope of ASP implementation.

Authors’ Contribution

F.K: Contributed to study design, data acquisition, and drafting the work. The author approved the final manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conflict of Interest

Fazlollah Keshavarzi, as the Editorial Board Member, was not involved in any stage of handling this manuscript. A team of independent experts were formed by the Editorial Board to review the editor’s article without his knowledge.

References

1. Brotherton AL. Metrics of Antimicrobial Stewardship Programs. Med Clin North Am. 2018;102:965-76. doi: 10.1016/j.mcna.2018.05.008. PubMed PMID: 30126585.

2. Beardsley JR, Williamson JC, Johnson JW, Luther VP, Wrenn RH, Ohl CC. Show me the money: long-term financial impact of an antimicrobial stewardship program. Infect Control Hosp Epidemiol. 2012;33:398-400. doi: 10.1086/664922. PubMed PMID: 22418636.

3. Barlam TF, Neuhauser MM, Tamma PD, Trivedi KK. Practical implementation of an antibiotic stewardship program. Cambridge: Cambridge University Press; 2018.

4. Naylor NR, Zhu N, Hulscher M, Holmes A, Ahmad R, Robotham JV. Is antimicrobial stewardship cost-effective? A narrative review of the evidence. Clin Microbiol Infect. 2017;23:806-11. doi: 10.1016/j.cmi.2017.06.011. PubMed PMID: 28642146.

5. Morgan AK, Awafo BA, Quartey T. The effects of COVID-19 on global economic output and sustainability: evidence from around the world and lessons for redress. Sustainability: Science, Practice and Policy. 2021;17:77-81. doi: 10.1080/15487733.2020.1860345.

6. Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53:1983-6. doi: 10.1128/AAC.01535-08. PubMed PMID: 19273670; PubMed Central PMCID: PMCPMC2681502.

7. Lima AL, Oliveira PR, Paula AP, Dal-Paz K, Almeida JN, Jr., Felix Cda S, et al. Carbapenem stewardship: positive impact on hospital ecology. Braz J Infect Dis. 2011;15:1-5. doi: 10.1016/s1413-8670(11)70131-3. PubMed PMID: 21412581.

8. Ahmad F, Pogue JM, Marchaim D, Chopra T, Bheemreddy S, Lee J, et al. Evaluation of the potential impact of a carbapenem de-escalation program in an academic healthcare system. J Infect Public Health. 2014;7:50-3. doi: 10.1016/j.jiph.2013.09.004. PubMed PMID: 24210246.

9. Yoon YK, Yang KS, Lee SE, Kim HJ, Sohn JW, Kim MJ. Effects of Group 1 versus Group 2 carbapenems on the susceptibility of Acinetobacter baumannii to carbapenems: a before and after intervention study of carbapenem-use stewardship. PLoS One. 2014;9:e99101. doi: 10.1371/journal.pone.0099101. PubMed PMID: 24911244; PubMed Central PMCID: PMCPMC4049602.

10. Viale P, Tumietto F, Giannella M, Bartoletti M, Tedeschi S, Ambretti S, et al. Impact of a hospital-wide multifaceted programme for reducing carbapenem-resistant Enterobacteriaceae infections in a large teaching hospital in northern Italy. Clin Microbiol Infect. 2015;21:242-7. doi: 10.1016/j.cmi.2014.10.020. PubMed PMID: 2568534.

11. Pérez Serrano R, Martín Siguero A, Porras Leal M, Castón Osorio J, González Gasca F, Abdelhadi Álvarez H, et al. CP-132 Impact of implementing a carbapenem stewardship program. European Journal of Hospital Pharmacy. 2015;22:A53. doi: 10.1136/ejhpharm-2015-000639.126.

12. Tagashira Y, Horiuchi M, Tokuda Y, Heist BS, Higuchi M, Honda H. Antimicrobial stewardship for carbapenem use at a Japanese tertiary care center: An interrupted time series analysis on the impact of infectious disease consultation, prospective audit, and feedback. Am J Infect Control. 2016;44:708-10. doi: 10.1016/j.ajic.2015.12.016. PubMed PMID: 26831278.

13. Delgado A, Lee GC, Gawrys GW, Duhon BM, Koeller JM. Impact of an Antimicrobial Stewardship Initiative on Ertapenem Use and Carbapenem Susceptibilities at Four Community Hospitals. Open Forum Infectious Diseases. 2015;2. doi: 10.1093/ofid/ofv133.1004.

14. Seah VXF, Ong RYL, Lim ASY, Chong CY, Tan NWH, Thoon KC. Impact of a
Carbapenem Antimicrobial Stewardship Program on Patient Outcomes. Antimicrob Agents Chemother. 2017;61. doi: 10.1128/AAC.00736-17. PubMed PMID: 28717037; PubMed Central PMCID: PMCPMC5571328.

15 Hwang H, Kim B. Impact of an infectious diseases specialist-led antimicrobial stewardship programmes on antibiotic use and antimicrobial resistance in a large Korean hospital. Sci Rep. 2018;8:14757. doi: 10.1038/s41598-018-0449-3. PubMed PMID: 30627429; PubMed Central PMCID: PMCPMC6322243.

16 Zhang D, Cui K, Lu W, Bai H, Zhai Y, Hu S, et al. Evaluation of carbapenem use in a tertiary hospital: antimicrobial stewardship urgently needed. Antimicrob Resist Infect Control. 2019;8:5. doi: 10.1186/s13756-018-0449-3. PubMed PMID: 30627429; PubMed Central PMCID: PMCPMC6322243.

17 Johnk SR, Grindeland CJ, Leedahl DD, Carson PJ, Leedahl ND. Impact of a multi-center stewardship-targeted carbapenem justification requirement on the use of carbapenems in 23 hospitals. Journal of the American College of Clinical Pharmacy. 2019;2:53-7. doi: 10.1002/jac5.1021.

18 Ruttimann S, Keck B, Hartmeier C, Maetzl A, Bucher HC. Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital. Clin Infect Dis. 2004;38:348-56. doi: 10.1086/380964. PubMed PMID: 14727204.

19 Sick AC, Lehmann CU, Tamma PD, Lee CK, Agwu AL. Sustained savings from a longitudinal cost analysis of an internet-based pre-approval antimicrobial stewardship program. Infect Control Hosp Epidemiol. 2013;34:573-80. doi: 10.1086/670625. PubMed PMID: 23651887.

20 Ansari F, Gray K, Nathwani D, Phillips G, Ogston S, Ramsay C, et al. Outcomes of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis. J Antimicrob Chemother. 2003;52:842-8. doi: 10.1093/jac/dkg459. PubMed PMID: 14563900.

21 Gums JG, Yancey RW, Jr., Hamilton CA, Kubilis PS. A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team. Pharmacotherapy. 1999;19:1369-77. doi: 10.1592/phco.19.18.1369.30898. PubMed PMID: 10600895.

22 Scheetz MH, Bolon MK, Postelnick M, Noskin GA, Lee TA. Cost-effectiveness analysis of an antimicrobial stewardship team on bloodstream infections: a probabilistic analysis. J Antimicrob Chemother. 2009;63:816-25. doi: 10.1093/jac/dkp004. PubMed PMID: 19202150.

23 Hamblin S, Rumbaugh K, Miller R. Prevention of adverse drug events and cost savings associated with PharmD interventions in an academic Level I trauma center: an evidence-based approach. J Trauma Acute Care Surg. 2012;73:1484-90. doi: 10.1097/TA.0b013e318267cd80. PubMed PMID: 23064610.

24 Lin YS, Lin IF, Yen YF, Lin PC, Shiu YC, Hu HY, et al. Impact of an antimicrobial stewardship program with multidisciplinary cooperation in a community public teaching hospital in Taiwan. Am J Infect Control. 2013;41:1069-72. doi: 10.1016/j.ajic.2013.04.004. PubMed PMID: 23870295.

25 Garcia-Rodriguez JF, Bardan-Garcia B, Pena-Rodriguez MF, Alvarez-Diaz H, Marino-Callejo A. Meropenem antimicrobial stewardship program: clinical, economic, and antibiotic resistance impact. Eur J Clin Microbiol Infect Dis. 2019;38:161-70. doi: 10.1007/s10096-018-3408-2. PubMed PMID: 30367313.

26 Delory T, De Pontfarcy A, Emirian A, About F, Berdougo B, Brun-Buisson C, et al. Impact of a program combining pre-authorization requirement and post-prescription review of carbapenems: an interrupted time-series analysis. Eur J Clin Microbiol Infect Dis. 2013;32:1599-604. doi: 10.1007/s10096-013-1918-5. PubMed PMID: 23839593.

27 Mouwen AMA, Dijkstra JA, Jong E, Buijtels P, Pasker-de Jong PCM, Nagtegaal JE. Early switching of antibiotic therapy from intravenous to oral using a combination of education, pocket-sized cards and switch advice: A practical intervention resulting in reduced length of hospital stay. Int J Antimicrob Agents. 2020;55:105769. doi: 10.1016/j.ijantimicag.2019.07.020. PubMed PMID: 31362046.

28 Niwa T, Shinoda Y, Suzuki A, Ohmori T, Yasuda M, Ohta H, et al. Outcome measurement of extensive implementation of antimicrobial stewardship in patients receiving intravenous antibiotics in a Japanese university hospital. Int J Clin Pract. 2012;66:1009-1014. doi: 10.1111/j.1471-1842.2012.02999.x. PubMed PMID: 22846073; PubMed Central PMCID: PMCPMC3489737.

29 Chandrasekhar D, PokkaVayalil V. Cost minimization analysis on IV to oral conversion of antimicrobial agent by the clinical pharmacist intervention. Clinical Epidemiology and
Global Health. 2019;7:60-5. doi: 10.1016/j.cejgh.2018.01.001.

30 Dik JW, Hendrix R, Friedrich AW, Luttijboer J, Panday PN, Wilting KR, et al. Cost-minimization model of a multidisciplinary antibiotic stewardship team based on a successful implementation on a urology ward of an academic hospital. PLoS One. 2015;10:e0126106. doi: 10.1371/journal.pone.0126106. PubMed PMID: 25955494; PubMed Central PMCID: PMCPMC4425554.

31 Slayton RB, Scott RD, Baggs J, Lessa FC, McDonald LC, Jernigan JA. The cost-benefit of federal investment in preventing Clostridium difficile infections through the use of a multifaceted infection control and antimicrobial stewardship program. Infect Control Hosp Epidemiol. 2015;36:681-7. doi: 10.1017/ice.2015.43. PubMed PMID: 25783204; PubMed Central PMCID: PMCPMC6550306.

32 Bhavnani SM, Ambrose PG. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. Diagn Microbiol Infect Dis. 2008;60:59-64. doi: 10.1016/j.diagmicrobio.2007.07.006. PubMed PMID: 17889491.

33 Collins CD, Brockhaus K, Sim T, Suneja A, Malani AN. Analysis to determine cost-effectiveness of procalcitonin-guided antibiotic use in adult patients with suspected bacterial infection and sepsis. Am J Health Syst Pharm. 2019;76:1219-25. doi: 10.1093/ajhp/zxz129. PubMed PMID: 31369118.

34 McKinnell JA, Corman S, Patel D, Leung GH, Gordon LM, Lodise TP. Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus. Clin Ther. 2018;40:406-14 e2. doi: 10.1016/j.clinthera.2018.01.010. PubMed PMID: 29454592.

35 Okumura LM, Riveros BS, Gomes-da-Silva MM, Veroneze I. A cost-effectiveness analysis of two different antimicrobial stewardship programs. Braz J Infect Dis. 2016;20:255-61. doi: 10.1016/j.bjid.2016.02.005. PubMed PMID: 27094234.

36 Ruiz-Ramos J, Frasquet J, Roma E, Poveda-Andres JL, Salvart-Leti M, Castellanos A, et al. Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units. J Med Econ. 2017;20:652-9. doi: 10.1080/13696998.2017.1311903. PubMed PMID: 28345481.

37 Voermans AM, Mewes JC, Broyles MR, Steuten LMG. Cost-Effectiveness Analysis of a Procalcitonin-Guided Decision Algorithm for Antibiotic Stewardship Using Real-World U.S. Hospital Data. OMICS. 2019;23:508-15. doi: 10.1089/omi.2019.0113. PubMed PMID: 31509068; PubMed Central PMCID: PMCPMC6806362.

38 So M, Mamdani MM, Morris AM, Lau TTY, Broady R, Deotare U, et al. Effect of an antimicrobial stewardship programme on antimicrobial utilisation and costs in patients with leukaemia: a retrospective controlled study. Clin Microbiol Infect. 2018;24:882-8. doi: 10.1016/j.cmi.2017.11.009. PubMed PMID: 29138099.

39 Gutierrez-Urbon JM, Gil-Navarro MV, Moreno-Ramos F, Nunez-Nunez M, Panopardo JR, Perianez-Parraga L. Indicators of the hospital use of antimicrobial agents based on consumption. Farm Hosp. 2019;43:94-100. doi: 10.7399/fh.11163. PubMed PMID: 31072287.

40 Thabit AK, Shea KM, Guzman OE, Garey KW. Antibiotic utilization within 18 community hospitals in the United States: A 5-year analysis. Pharmacoepidemiol Drug Saf. 2021;30:403-8. doi: 10.1002/pds.5156. PubMed PMID: 33094502.

41 Xiao Y, Shen P, Zheng B, Zhou K, Luo Q, Li L. Change in Antibiotic Use in Secondary and Tertiary Hospitals Nationwide After a National Antimicrobial Stewardship Campaign Was Launched in China, 2011-2016: An Observational Study. J Infect Dis. 2020;221:S148-S55. doi: 10.1093/infdis/jiz556. PubMed PMID: 32176788.

42 Jover-Saenz A, Ramirez-Hidalgo MF, Vidal MV, Gonzalez MG, Cano Marron SM, Arias AE, et al. Antimicrobial stewardship program at a tertiary care academic medical hospital: Clinical, microbiological and economic impact. A 5-year temporary descriptive study. Infect Prev Pract. 2020;2:100048. doi: 10.1016/j.infpip.2020.100048. PubMed PMID: 34368698; PubMed Central PMCID: PMCPMC8335906.

43 Mewes JC, Pullia MS, Mansour MK, Broyles MR, Nguyen HB, Steuten LM. The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis. PLoS One. 2019;14:e0214222. doi: 10.1371/journal.pone.0214222. PubMed PMID: 31013271; PubMed Central PMCID: PMCPMC6478294.

44 Stocker H, Mehlhorn C, Jordan K, Eckholt L,
Jefferys L, Arasteh K. Clinical and economic effects of an antimicrobial stewardship intervention in a surgical intensive care unit. Infection. 2020;48:509-19. doi: 10.1007/s15010-020-01421-8. PubMed PMID: 32277409.

45 Onorato L, Macera M, Calo F, Monari C, Russo F, Iovene MR, et al. The effect of an antimicrobial stewardship programme in two intensive care units of a teaching hospital: an interrupted time series analysis. Clin Microbiol Infect. 2020;26:782. doi: 10.1016/j.cmi.2019.10.021. PubMed PMID: 31678230.

46 Penalva G, Fernandez-Urrusuno R, Turmo JM, Hernandez-Soto R, Pajares I, Carrion L, et al. Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in the community: an interrupted time-series analysis. Lancet Infect Dis. 2020;20:199-207. doi: 10.1016/S1473-3099(19)30573-0. PubMed PMID: 31767423.

47 Scott RD, 2nd, Slayton RB, Lessa FC, Baggs J, Culler SD, McDonald LC, et al. Assessing the social cost and benefits of a national requirement establishing antibiotic stewardship programs to prevent Clostridiodides difficile infection in US hospitals. Antimicrob Resist Infect Control. 2019;8:17. doi: 10.1186/s13756-018-0459-1. PubMed PMID: 30680153; PubMed Central PMCID: PMCPMC6343309.

48 Vazin A, Karimzadeh I, Karamikhah R, Oveis Z, Mohseni S, Keykhae M, et al. Clinical and economical impacts of guideline implementation by the pharmaceutical care unit for high cost medications in a referral hospital. BMC Health Serv Res. 2018;18:815. doi: 10.1186/s12913-018-3627-3. PubMed PMID: 30355286; PubMed Central PMCID: PMCPMC6201544.

49 Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford university press; 2015.

50 Haley RW. Measuring the costs of nosocomial infections: methods for estimating economic burden on the hospital. Am J Med. 1991;91:325S-8S. doi: 10.1016/0002-9343(91)90341-t. PubMed PMID: 1928186.

51 Howard D, Cordell R, McGowan JE, Jr., Packard RM, Scott RD, 2nd, Solomon SL, et al. Measuring the economic costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention-Emory Workshop. Clin Infect Dis. 2001;33:1573-8. doi: 10.1086/323758. PubMed PMID: 11577379.

52 Bennett N, Schulz L, Boyd S, Newland JG. Understanding inpatient antimicrobial stewardship metrics. Am J Health Syst Pharm. 2018;75:230-8. doi: 10.2146/ajhp160335. PubMed PMID: 29436469.

53 Johansson B, Beekmann SE, Srinivasan A, Hersh AL, Laxminarayan R, Polgreen PM. Improving antimicrobial stewardship: the evolution of programmatic strategies and barriers. Infect Control Hosp Epidemiol. 2011;32:367-74. doi: 10.1086/658946. PubMed PMID: 21460488.

54 Nathwani D, Varghese D, Stephens J, Ansari W, Martin S, Charbonneau C. Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review. Antimicrob Resist Infect Control. 2019;8:35. doi: 10.1186/s13756-019-0471-0. PubMed PMID: 30805182; PubMed Central PMCID: PMCPMC6373132.

55 Wilson JP, Rascati KL. Pharmacoconomics. In: Malone PM, editors. Drug Information A Guide for Pharmacists. Fifth ed. New York: McGraw-Hill Education; 2014.

56 Roberts RR, Hota B, Ahmad I, Scott RD, 2nd, Foster SD, Abbasi F, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009;49:1175-84. doi: 10.1086/605630. PubMed PMID: 19739972.

57 Michaelidis CI, Fine MJ, Lin CJ, Linder JA, Nowalk MP, Shields RK, et al. The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis. BMC Infect Dis. 2016;16:655. doi: 10.1186/s12879-016-1990-4. PubMed PMID: 27825306; PubMed Central PMCID: PMCPMC5101711.

58 WHO Collaborating Centre for Drug Statistics Methodology [Internet]. Guidelines for ATC classification and DDD assignment. c2014. Available from: https://www.whocc.no/atc_ddd_index.

59 Hutchinson JM, Patrick DM, Marra F, Ng H, Bowie WR, Heule L, et al. Measurement of antibiotic consumption: A practical guide to the use of the Anatomical Thgerapeutic Chemical classification and Defined Daily Dose system methodology in Canada. Can J Infect Dis. 2004;15:29-35. doi: 10.1155/2004/389092. PubMed PMID: 18159441; PubMed Central PMCID: PMCPMC2094921.

60 Strom BL. Pharmacoepidemiology. University of Pennsylvania. Philadelphia: John
Wiley & Sons, Ltd; 2005.

61 Dahlui M, Wan NC, Koon TS. Cost analysis of UMMC services: estimating the unit cost for outpatient and inpatient services. BMC Health Services Research. 2012;12:1-2. doi: 10.1186/1472-6963-12-S1-O1.

62 Advani P, Alves J, Bekele B, Bentley F, Norris D, Patel R, et al. TrendWatch Chartbook 2016. Chicago: American Hospital Association; 2016.

63 Taheri PA, Butz DA, Greenfield LJ. Length of stay has minimal impact on the cost of hospital admission. J Am Coll Surg. 2000;191:123-30. doi: 10.1016/s1072-7515(00)00352-5. PubMed PMID: 10945354.

64 Lanbeck P, Ragnarson Tennvall G, Resman F. A cost analysis of introducing an infectious disease specialist-guided antimicrobial stewardship in an area with relatively low prevalence of antimicrobial resistance. BMC Health Serv Res. 2016;16:311. doi: 10.1186/s12913-016-1565-5. PubMed PMID: 27464508; PubMed Central PMCID: PMCPMC4963928.

65 Horn SD, Horn RA, Sharkey PD. The Severity of Illness Index as a severity adjustment to diagnosis-related groups. Health Care Financ Rev. 1984;Suppl:33-45. PubMed PMID: 10311075; PubMed Central PMCID: PMCPMC4195109.

66 Morris AM. Antimicrobial Stewardship Programs: Appropriate Measures and Metrics to Study their Impact. Curr Treat Options Infect Dis. 2014;6:101-12. doi: 10.1007/s40506-014-0015-3. PubMed PMID: 25999798; PubMed Central PMCID: PMCPMC4431704.

67 Coulter S, Merollini K, Roberts JA, Graves N, Halton K. The need for cost-effectiveness analyses of antimicrobial stewardship programmes: A structured review. Int J Antimicrob Agents. 2015;46:140-9. doi: 10.1016/j.ijantimicag.2015.04.007. PubMed PMID: 26058776.

68 You J. Antimicrobial stewardship programs - cost-minimizing or cost-effective? Expert Opin Pharmacother. 2015;16:155-7. doi: 10.1517/14656566.2015.973854. PubMed PMID: 25331093.